Home
Live Updates
FDA Approves First Biosimilar of Natalizumab for the Treatment of Relapsing Multiple Sclerosis : comparemela.com
FDA Approves First Biosimilar of Natalizumab for the Treatment of Relapsing Multiple Sclerosis
The FDA is the first regulatory agency globally to approve natalizumab-sztn as a biosimilar for natalizumab.
Related Keywords
United States ,
Polpharma Biologics ,
Michael Soldan ,
European Medicines Agency ,
Elan Pharmaceuticals Inc ,
Polpharma Biologics Group ,
National Institutes Of Neurological Disorders ,
Multiple Sclerosis Journal ,
Polpharma Biologic ,
Risk Evaluation ,
Mitigation Strategy ,
Neurological Disorders ,
Updated January ,
comparemela.com © 2020. All Rights Reserved.